StreetInsider.com News Articles

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26747571.html

Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward

Wed, 08 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26747571.html

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

The analyst commented, "This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich’s Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic’s ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and $18 risk-adjusted, DCF-derived price target. Ms. Farmer will be able to provide additional context on nomlabofusp’s perceived benefit/risk profile from the patient community perspective. Additionally, we plan to discuss real world feedback on Skyclarys’

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens

Tue, 07 Jul 2026 05:21:09 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $18.00 price target on Larimar Therapeutics (NASDAQ: LRMR).

H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy

Thu, 02 Jul 2026 06:46:59 -0400

(Updated - July 2, 2026 6:46 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju assumes coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Buy rating and a price target of $10.00.

The analyst comments "BLA submission completion seeking accelerated approval on track for 2H26—assuming coverage at Buy. We are assuming coverage of Larimar Therapeutics with a Buy rating and 12-month price target of $10 per share. Investors are reminded that Larimar is gearing up to complete its Biologics License Application (BLA) for nomlabofusp later this year; in our view, the filing is likely to receive Priority Review. Nomlabofusp is a subcutaneously administered, recombinant

H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy

Thu, 02 Jul 2026 06:46:59 -0400

(Updated - July 2, 2026 6:46 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju assumes coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Buy rating and a price target of $10.00.

Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird

Tue, 30 Jun 2026 06:54:02 -0400

Baird analyst Joel Beatty lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $5.00 (from $7.00) while maintaining a Outperform rating.

Form 8-K Larimar Therapeutics, For: Jun 29

Mon, 29 Jun 2026 06:34:00 -0400

si-local-file:///var/storage/secattach/20260629/26701658.html

Form 8-K Larimar Therapeutics, For: Jun 29

Mon, 29 Jun 2026 06:34:00 -0400

si-local-file:///var/storage/secattach/20260629/26701658.html

Larimar files first BLA module for Friedreich's ataxia drug

Mon, 29 Jun 2026 06:30:57 -0400

Larimar Therapeutics (Nasdaq: LRMR) submitted the first module of a rolling Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for Friedreich's ataxia (FA), a rare progressive neurological disease. The remaining modules are expected in the second half of 2026.

The submission follows FDA meeting minutes from a Type B multidisciplinary pre-BLA meeting, in which the agency confirmed the existing data package appears sufficient to support a BLA submission seeking accelerated approval, with skin frataxin (FXN) as a potential novel surrogate endpoint. The FDA also agreed to a rolling submission format.

Larimar also released updated

Larimar files first BLA module for Friedreich's ataxia drug

Mon, 29 Jun 2026 06:30:57 -0400

Larimar also released updated

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Mon, 29 Jun 2026 06:30:00 -0400

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026
Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants achieved and maintained levels over 50% of mean levels in healthy volunteers (comparable to asymptomatic heterozygous carriers) at 1-year
Continued directional improvement across mFARS, FARS-ADL, 9-HPT, MFIS observed at 1 year of nomlabofusp treatment (n = 13) relative to a worsening in a FACOMS natural history study reference population
One of six non-ambulatory participants at baseline

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Mon, 29 Jun 2026 06:30:00 -0400

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026
Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants achieved and maintained levels over 50% of mean levels in healthy volunteers (comparable to asymptomatic heterozygous carriers) at 1-year
Continued directional improvement across mFARS, FARS-ADL, 9-HPT, MFIS observed at 1 year of nomlabofusp treatment (n = 13) relative to a worsening in a FACOMS natural history study reference population
One of six non-ambulatory participants at baseline

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Mon, 29 Jun 2026 06:30:00 -0400

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026
Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants achieved and maintained levels over 50% of mean levels in healthy volunteers (comparable to asymptomatic heterozygous carriers) at 1-year
Continued directional improvement across mFARS, FARS-ADL, 9-HPT, MFIS observed at 1 year of nomlabofusp treatment (n = 13) relative to a worsening in a FACOMS natural history study reference population
One of six non-ambulatory participants at baseline

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Mon, 29 Jun 2026 06:30:00 -0400

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026
Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants achieved and maintained levels over 50% of mean levels in healthy volunteers (comparable to asymptomatic heterozygous carriers) at 1-year
Continued directional improvement across mFARS, FARS-ADL, 9-HPT, MFIS observed at 1 year of nomlabofusp treatment (n = 13) relative to a worsening in a FACOMS natural history study reference population
One of six non-ambulatory participants at baseline

Larimar Therapeutics to host investor event on June 29

Fri, 26 Jun 2026 16:05:49 -0400

Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced it will host an investor webcast on June 29, 2026, at 7:45 a.m. ET to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia.
The event is expected to include a regulatory update and data from the company's ongoing long-term open-label study of nomlabofusp, which is being developed as a potential treatment for adults and children with Friedreich's ataxia.
An archived recording of the webcast will be made available on the company's website following the live event.

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Fri, 26 Jun 2026 16:05:00 -0400

Webcast on Monday, June 29, 2026, at 7:45 am ET

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Webcast Details
To access the webcast on Monday, June 29,

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Fri, 26 Jun 2026 16:05:00 -0400

Webcast on Monday, June 29, 2026, at 7:45 am ET

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Webcast Details
To access the webcast on Monday, June 29,

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Fri, 26 Jun 2026 16:05:00 -0400

Webcast on Monday, June 29, 2026, at 7:45 am ET

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Webcast Details
To access the webcast on Monday, June 29,

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Fri, 26 Jun 2026 16:05:00 -0400

Webcast on Monday, June 29, 2026, at 7:45 am ET

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Webcast Details
To access the webcast on Monday, June 29,

JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight

Wed, 27 May 2026 01:09:42 -0400

JPMorgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Overweight rating and a price target of $9.00.
The analyst comments: “We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. Larimar’s lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich’s ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company’s type B

JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight

Wed, 27 May 2026 01:09:42 -0400

JPMorgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Overweight rating and a price target of $9.00.
The analyst comments: “We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. Larimar’s lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich’s ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company’s type B

Form 4 Larimar Therapeutics, For: May 19 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P.

Wed, 20 May 2026 20:03:00 -0400
si-local-file:///var/storage/secattach/20260520/26529969.html